Carbamazepine
1
Reactions 1401 - 12 May 2012 S Carbamazepine Hyponatraemia in elderly patients: 2 case reports Two women, aged 74 and 69 years, developed hyponatraemia while receiving carbamazepine [routes not stated] for epilepsy. The older woman, who had a history of chronic renal disease and hypopituitarism, started antiepileptic therapy with carbamazepine (2x 150mg) [frequency not clearly stated] following an epileptic paroxysmal event. Despite treatment, recurrent seizures were observed and, 48 hours after starting carbamazepine, she displayed a marked worsening of consciousness, with somnolence and quadraparesis. Laboratory analysis showed life-threatening hyponatraemia after 3 days of carbamazepine therapy, although an initial decrease in her sodium level had been observed after 24 hours. Antiepileptic therapy was changed to phenytoin and her serum sodium level increased. Her consciousness level normalised, with no epileptic episodes during the course of hospitalisation. The younger woman, who had a history of epilepsy treated long-term with carbamazepine [dosage and duration of treatment to reaction onset not stated], presented with symptomatic, profound hyponatraemia. On admission, she was disorientated and somnolent, and she received hydration and sodium supplementation. Imaging studies confirmed the presence of a suspected left adrenal adenoma, but a paraneoplastic aetiology of hyponatraemia was unconfirmed. Carbamazepine was withdrawn and her serum sodium level normalised. She was fully orientated upon discharge and her serum sodium level was normal at last observation. Dedinska I, et al. Hyponatremia - Carbamazepine medication complications. Vnitrni lekarstvi 58: 72-75, No. 1, Jan 2012 [Czech; summarised from a translation] - Slovakia 803070128 1 Reactions 12 May 2012 No. 1401 0114-9954/10/1401-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Carbamazepine
Reactions 1401 - 12 May 2012
SCarbamazepine
Hyponatraemia in elderly patients: 2 case reportsTwo women, aged 74 and 69 years, developed
hyponatraemia while receiving carbamazepine [routes notstated] for epilepsy.
The older woman, who had a history of chronic renaldisease and hypopituitarism, started antiepileptic therapywith carbamazepine (2x 150mg) [frequency not clearlystated] following an epileptic paroxysmal event. Despitetreatment, recurrent seizures were observed and, 48 hoursafter starting carbamazepine, she displayed a markedworsening of consciousness, with somnolence andquadraparesis. Laboratory analysis showed life-threateninghyponatraemia after 3 days of carbamazepine therapy,although an initial decrease in her sodium level had beenobserved after 24 hours. Antiepileptic therapy was changedto phenytoin and her serum sodium level increased. Herconsciousness level normalised, with no epileptic episodesduring the course of hospitalisation.
The younger woman, who had a history of epilepsytreated long-term with carbamazepine [dosage andduration of treatment to reaction onset not stated],presented with symptomatic, profound hyponatraemia. Onadmission, she was disorientated and somnolent, and shereceived hydration and sodium supplementation. Imagingstudies confirmed the presence of a suspected left adrenaladenoma, but a paraneoplastic aetiology of hyponatraemiawas unconfirmed. Carbamazepine was withdrawn and herserum sodium level normalised. She was fully orientatedupon discharge and her serum sodium level was normal atlast observation.Dedinska I, et al. Hyponatremia - Carbamazepine medication complications.Vnitrni lekarstvi 58: 72-75, No. 1, Jan 2012 [Czech; summarised from atranslation] - Slovakia 803070128
1
Reactions 12 May 2012 No. 14010114-9954/10/1401-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
